SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology Inc. (Nasdaq: VIR) today announced that Jason O’Byrne, MBA, is appointed as Executive Vice President and Chief Financial Officer (CFO), effective October 2, 2024. Mr. O’Byrne will join the Vir Executive Management Team and report directly to the company’s Chief Executive Officer, Marianne De Backer, M.Sc., Ph.D., MBA..

旧金山——（商业新闻短讯）——Vir Biotechnology Inc.（纳斯达克：Vir）今天宣布，MBA杰森·奥伯恩（JasonO'Byrne）被任命为执行副总裁兼首席财务官（CFO），自2024年10月2日起生效。O'Byrne先生将加入Vir执行管理团队，直接向公司首席执行官Marianne De Backer（硕士、博士、MBA）汇报工作。。

Mr. O’Byrne is an accomplished executive with more than 20 years of experience in finance and operations. He is a recognized champion of financial discipline and brings demonstrated financial leadership in capital allocation and formation, corporate strategy, and operational execution.

奥伯恩先生是一位多才多艺的高管，拥有20多年的财务和运营经验。他是公认的财务纪律倡导者，在资本分配和形成、公司战略和运营执行方面表现出财务领导力。

Mr. O’Byrne joins Vir from Caribou Biosciences, Inc., where he served as CFO leading the finance, investor relations, corporate communications, IT, procurement and operations functions as the company advanced its pipeline of clinical-stage cell therapies in oncology and autoimmune disease. Prior to joining Caribou, Mr.

O'Byrne先生从Caribou Biosciences，Inc.加入Vir，担任首席财务官，领导财务、投资者关系、企业沟通、IT、采购和运营职能，因为该公司推进了其在肿瘤学和自身免疫性疾病中的临床阶段细胞治疗管道。在加入北美驯鹿之前。

O’Byrne served as Senior Vice President of Finance at Audentes Therapeutics, where he led financial operations of the gene therapy company. While at Audentes, Mr. O’Byrne oversaw the financial due diligence and integration related to the company’s acquisition by Astellas Pharma in 2020..

O'Byrne曾担任Audentes Therapeutics的财务高级副总裁，负责基因治疗公司的财务运营。在Audentes任职期间，O'Byrne先生监督了与2020年Astellas Pharma收购该公司有关的财务尽职调查和整合。。

Earlier in his career, Mr. O’Byrne held roles of increasing responsibility and geographical reach at Genentech, a member of the Roche group. Over a 13-year period with Genentech, he built broad operational finance expertise across manufacturing, research, clinical development, business development and commercialization.

在职业生涯的早期，奥伯恩先生在罗氏集团的成员基因泰克（Genentech）担任越来越重要的职责和地理范围。在Genentech任职的13年中，他在制造、研究、临床开发、业务开发和商业化方面积累了广泛的运营财务专业知识。

During his tenure, he served as Regional Head of Commercial Finance for the Asia Pacific Region, and Global Head of Finance for Product Development. Mr. O’Byrne holds a Bachelor of Applied Science in Mechanical Engineering from the University of British Columbia, and an MBA in Finance from the New York University Stern School of Business..

在任职期间，他曾担任亚太地区商业金融区域负责人和产品开发全球金融负责人。O'Byrne先生拥有不列颠哥伦比亚大学机械工程应用科学学士学位和纽约大学斯特恩商学院金融MBA学位。。

“I am delighted to welcome Jason to the Vir Executive Management Team and excited about the impact he will bring to Vir. Jason’s exceptional leadership coupled with his proven track record in financial strategy across public companies, make him the perfect fit as we embark on the next chapter for our organization,” said Marianne De Backer, Chief Executive Officer, Vir Biotechnology.

Vir Biotechnology首席执行官玛丽安·德巴克（MarianneDeBacker）表示：“我很高兴欢迎杰森加入Vir执行管理团队，并对他将给Vir带来的影响感到兴奋。杰森出色的领导力加上他在上市公司财务战略方面的良好记录，使他成为我们开始公司下一章的最佳人选。”。

“As a seasoned and well-respected cross-functional leader with a focus on excellence in execution, I look forward to partnering with Jason as we advance in our mission of powering the immune system to transform lives.”.

。

“I am honored to join Vir at this important time as it expands into oncology and continues the innovative work to address unmet patient need in infectious disease,” said Mr. O’Byrne. “I admire Vir’s proven ability to accelerate differentiated antibody therapeutics. I am excited to join the talented team and contribute to rapidly advancing important new therapeutic options for patients.”.

O'Byrne先生说：“我很荣幸在这个重要的时刻加入Vir，因为它扩展到肿瘤学领域，并继续创新工作，以解决传染病患者未满足的需求。”。“我钦佩Vir在加速分化抗体治疗方面的成熟能力。我很高兴加入这个有才能的团队，为快速推进患者重要的新治疗选择做出贡献。”。

About Vir Biotechnology, Inc.

关于Vir Biotechnology，Inc。

Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Vir’s clinical-stage portfolio includes infectious disease programs for chronic hepatitis delta and chronic hepatitis B infections, in addition to multiple oncology programs.

Vir Biotechnology，Inc.是一家临床阶段的生物制药公司，专注于通过发现和开发治疗严重传染病和癌症的药物来增强免疫系统以改变生活。Vir的临床阶段投资组合包括针对慢性三角型肝炎和慢性乙型肝炎感染的传染病计划，以及多种肿瘤学计划。

Vir also has a preclinical portfolio of programs across a range of other infectious diseases and oncologic malignancies. Vir routinely posts information that may be important to investors on its website..

Vir还拥有一系列其他传染病和恶性肿瘤的临床前项目组合。Vir定期在其网站上发布对投资者可能很重要的信息。。

Forward-Looking Statements

前瞻性声明

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “plan,” “potential,” “aim,” “expect,” “anticipate,” “promising” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements.

本新闻稿包含1995年《私人证券诉讼改革法案》所指的前瞻性声明。诸如“可能”、“将”、“计划”、“潜在”、“目标”、“期望”、“预期”、“有希望”等词语和类似表达（以及其他涉及未来事件、条件或情况的词语或表达）旨在识别前瞻性陈述。

These forward-looking statements are based on Vir’s expectations and assumptions as of the date of this press release. Forward-looking statements contained in this press release include, but are not limited to, statements regarding Vir’s strategy and plans, and its expectations related thereto, and potential of, and expectations for, Vir’s pipeline.

。本新闻稿中包含的前瞻性声明包括但不限于有关Vir战略和计划的声明，以及与之相关的期望，以及Vir管道的潜力和期望。

Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data or results observed during clinical trials or in data readouts; the occurrence of adverse safety events; risks of unexpected costs, delays or other unexpected hurdles; difficulties in collaborating with other companies; successful development and/or commercialization of alternative product candidates by Vir’s competitors; changes in expected or existing competition; delays in or disruptions to Vir’s business or clinical trials due to geopolitical changes or other external factors; and unexpected litigation or other disputes.

许多因素可能会导致当前预期与实际结果之间的差异，包括意外的安全性或有效性数据或在临床试验或数据读数中观察到的结果；不良安全事件的发生；意外成本、延误或其他意外障碍的风险；与其他公司合作困难；Vir的竞争对手成功开发和/或商业化替代产品候选产品；预期或现有竞争的变化；由于地缘政治变化或其他外部因素，Vir业务或临床试验延迟或中断；以及意外诉讼或其他纠纷。

Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval.

药物开发和商业化涉及高度风险，只有少数研究和开发计划会导致产品商业化。早期临床试验的结果可能不能表明全部结果或后期或大规模临床试验的结果，也不能确保监管部门的批准。

You should not place undue reliance on thes.

你不应该过分依赖这些。